Migraine is considered to be a polygenic multifactorial disease with various environmental and genetic etiologies. We investigated glutathione S-transferase (GST) P1 Ile105Val, T1 and M1 polymorphisms in 174 Japanese headache sufferers and 372 Japanese controls. The headache group consisted of 38 cases of migraine with aura, 95 migraine without aura (MWOA) and 41 tension-type headache sufferers. The M1 homozygous deletion genotype was significantly higher in MWOA (64%) compared with controls (46%; p < 0.01; odds ratio = 2.18, 95% confidence interval: 1.32–3.61, adjusted for age and gender). In a comparison of the current smokers, the M1 null frequencies in MWOA were further increased. GSTM1 may be one of the genetic risk factors for MWOA in the Japanese population.

Keywords:
Genetic association study, Migraine, Smoking, Risk factor
1.
Montagna P: Molecular genetics of migraine headaches: A review. Cephalalgia 2000;20:3–14.
2.
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–552.
3.
Ferrari MD: Migraine. Lancet 1998;351:1043–1051.
4.
Peroutka SJ, Wilhoit T, Jones K: Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco I alleles. Neurology 1997;49:201–206.
5.
Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000;96:762–764.
6.
Paterna S, di Pasquale P, D’Angelo A, Seidita G, Tuttolomondo A, Cardinale A, Maniscalchi T, Follone G, Giubilato A, Tarantello M, Licata G: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133–136.
7.
Terwindt GM, Ophoff RA, van Eijk R, Vergouwe MN, Haan J, Frants RR, Sandkuijl LA, Ferrari MD: Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 2001;56:1028–1032.
8.
Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB: The relative role of genetic and environmental factors in migraine without aura. Neurology 1999;53:995–999.
9.
Mannervik B: The isozymes of glutathione transferase. Adv Enzymol Relat Areas Mol Biol 1985;57:357–417.
10.
Hayes JD, Strange RC: Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res 1995:22:193–207.
11.
Harris MJ, Coggan M, Langton L, Wilson SR, Board PG: Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998;8:27–31.
12.
Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, Itoh H, Matsumoto T, Kawamoto T, Bell DA: Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer, oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 1999;9:165–169.
13.
Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999;83:606–609.
14.
Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA: Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996;347:295–297.
15.
Strange RC, Matharoo B, Faulder GC, Jones P, Cotton W, Elder JB, Deakin M: The human glutathione S-transferases: A case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis 1991;12:25–28.
16.
Mattsson P, Bjelfman C, Lundberg PO, Rane A: Cytochrome P450 2D6 and glutathione S-transferase M1 genotypes and migraine. Eur J Clin Invest 2000;30:367–371.
17.
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1–96.
18.
Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG: Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998;352:1344–1346.
19.
Michael A, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L, Oesch F: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996;236:184–186.
20.
Payne TJ, Stetson B, Stevens VM, Johnson CA, Penzien DB, Van Dorsten B: The impact of cigarette smoking on headache activity in headache patients. Headache 1991;31:329–332.
21.
Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J: Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 1999;19:660–667.
22.
Messina ES, Tyndale RF, Sellers EM: A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282:1608–1614.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.